logo-loader
viewSummit Therapeutics PLC

Director/PDMR Shareholding

Summit Therapeutics plc
(“Summit Therapeutics” or the “Company”)

Notification of Transaction of Persons Discharging Managerial Responsibilities

Oxford, UK, and Cambridge, MA, US, 10 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 7 February 2020, Dr Elaine Stracker, a Non-Executive Director of the Company, was assigned for no consideration warrants to acquire a total of 2,099,207 ordinary shares by Maky Zanganeh and Associates, Inc. (“MZA”). The Company has a consultancy agreement with MZA where Dr Stacker serves as General Counsel and Senior Vice President for Corporate Development

Following the completion of this transfer, Dr Stracker has the following interest in the Company’s ordinary shares:

  Total number of ordinary shares heldNumber of Outstanding Share Options HeldTotal Number of Outstanding Warrants Held
Elaine StrackerNon-Executive DirectorNil1,000,0002,099,207

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person responsible for arranging for the release of this announcement on behalf of the Company is Richard Pye, Vice President, Investor Relations and Corporate Affairs.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics to treat infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

For more information, please contact:

Summit  
Glyn Edwards / Richard Pye (UK office)Tel:44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
   
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson / Ludovico Lazzaretti  
   



The information set out below is provided in accordance with the requirements of Article 19(3) of the Market Abuse Regulation (EU) No 596/2014.

1Details of the persons discharging managerial responsibilities/person closely associated
a)Name (i)  Dr Elaine Stracker
2Reason for the notification
a)Position / status (i)  Non-Executive Director
b)Initial notification / AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameSummit Therapeutics plc
b)LEI213800NRW8AOMYMTBD89
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary shares of 1 penny each
  
Identification codeGB00BN40HZ01
b)Nature of the transactionsAssignment of warrants, for no consideration, to acquire ordinary shares of one penny nominal value at a price of 22.1 pence per ordinary share
c)Price(s) and volume(s) Price(s)Volume(s) 
(i) nil

 
 (i)  2,099,207
 
d)Aggregated information

 

- Aggregated volume

 

- Price
 

 

2,099,207 warrants to acquire ordinary shares

 

nil

 
e)Date of the transactions7 February 2020
f)Place of the transactionsOutside a trading venue

-END-

Quick facts: Summit Therapeutics PLC

Price: -

Market: AIM
Market Cap: -
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

on 9/12/19